by increasing cytoplasmic pH 24 (Fig. 1a) . By contrast, neither the H + gradient nor diethanolamine triggered NorM-NG-mediated R6G efflux in Escherichia coli. Because NorM-NG functions as a Na + -coupled multidrug transporter 8, 15 , these results suggested that recombinant DinF-BH was expressed as a functional multidrug transporter to effect H + -coupled drug efflux.
To confirm the H + coupling, we analyzed H + flux in a drug/H + antiport assay by measuring the changes in fluorescence quenching in everted membrane vesicles 9, 24, 25 . We found that the addition of a substrate, TPP, elicited efflux of H + in DinF-BH-containing membrane vesicles and caused fluorescence dequenching (Fig. 1b) . By contrast, everted membrane vesicles containing NorM-NG showed no response to TPP. Furthermore, we examined the cation dependence of DinF-BH-mediated transport by measuring drug accumulation levels in bacteria 8 . As a comparison, the accumulation of drugs in cells expressing Na + -coupled NorM-NG was lower in the presence of Na + than of K + (Fig. 1c) . By contrast, we observed no measurable difference in drug accumulation in cells expressing DinF-BH when Na + was replaced by K + . Altogether, our data supported DinF-BH as an H + -coupled rather than Na + -coupled transporter.
Structure overview of DinF-BH
To gain further mechanistic insights into DinF-BH-mediated transport, we determined its crystal structure at 3.2-Å resolution by combining molecular replacement and multiple isomorphous replacement and anomalous scattering (MIRAS) phasing (Supplementary Fig. 1 and Table 1 ). Each asymmetric unit revealed one DinF-BH molecule ( Fig. 2 and Supplementary Fig. 2 ) containing 12 membrane-spanning helices (TM1-TM12) with both N and C termini facing the cytoplasm, as is typical for MATE transporters of known structure 14, 15 .
In both NorM-VC and NorM-NG, the TM1-TM6 region is structurally related to TM7-TM12 around a pseudo-two-fold rotational axis running approximately perpendicular to the membrane plane. The structures of the two domains in NorM-NG could be superimposed onto each other with an r.m.s. deviation of 2.39 Å for 142 common Cα positions. By contrast, structural superimposition of the two domains in DinF-BH yielded an r.m.s. deviation of 3.30 Å for 138 common Cα positions. The most notable difference between the two halves of DinF-BH is localized in the extracellular halves of TM7 and TM8 (residues 253-288) and their counterparts in TM1 and TM2 (Supplementary Fig. 2 ). If those residues were excluded, the r.m.s. deviation could be lowered to 2.50 Å over 108 Cα atoms. Compared with TM1 and TM2, both TM7 and TM8 are more 'kinked' near their midsections, and those kinks appear to be induced by P247 and P291, respectively. In order to align closely with their counterparts in TM1 and TM2, the extracellular halves of TM7 and TM8 in DinF-BH need to tilt 20° relative to the membrane normal in order to straighten the kinks.
Wide crevice within the C domain
The structural 'asymmetry' of DinF-BH creates a wide crevice within its C domain, which is open to both the periplasm and outermembrane leaflet (Fig. 2a,b and Supplementary Fig. 2 ). This crevice effectively separates the C domain into two layers of helices, with TM7 and TM8 aligned in one and TM9-TM12 in the other. This separation suggests that substantial structural rearrangement in DinF-BH is needed to form a similar cation-binding site to that of NorM transporters 14 requiring close interhelical packing between TM7-TM8 and TM9-TM12 (Fig. 2c,d) . Notably, all DinF transporters lack the cation-binding motif that is conserved in the NorM branch, a motif exemplified by E261 (TM7), Y294 (TM8) and D377 (TM10) in NorM-NG 15 . The absence of conserved protonatable amino acids in the C domain of DinF-BH therefore implies a cation-binding site distinct from that of NorM transporters.
Rather than interacting closely with TM9-TM12 as in NorM transporters, the extracellular halves of TM7 and TM8 in DinF-BH bend back and pack snugly against TM2 and TM1, respectively (Fig. 2b) . In so doing, TM1-TM8 collectively forms an internal 'chamber' that can potentially shelter encapsulated substrate. The interior of the chamber is populated with numerous hydrophobic amino acids, whose bulky side chains can insulate the bound substrate from the outside environment. Additionally, TM7 and TM8 define a lateral fenestration through which H + from the solvent-filled crevice can gain access to the internal chamber (Supplementary Fig. 2 ). At the widest point within the membrane bilayer, the fenestration is 10 Å wide; this opening could also allow substrate to slide sideways out of the chamber and into the crevice. The access to the chamber from the cytoplasm side, however, is completely blocked by highly ordered protein structure.
Identification of the substrate-binding site
To locate the drug-binding site, we soaked cationic substrate R6G into the DinF-BH crystals and determined the structure to 3.7-Å Fig. 3 and Table 2 ). The experimental phases improved the observable/parameter ratio during structure refinement and allowed us to objectively examine possible drug-induced protein conformational changes. Furthermore, the experimental electron density map revealed a prominent electron density feature within the internal chamber that well matched the bound substrate (Fig. 3) . This density feature strictly depended on the incubation with R6G, as we had never observed such density in the apo form. Notably, the well-resolved electron density enabled us to define the orientation of the bound substrate with confidence ( Fig. 3b and Supplementary Fig. 3 ). Moreover, we calculated anomalous difference Fourier maps, using data collected on crystals incubated in solutions containing tetraphenylarsonium, a TPP analog 26 and also a substrate for DinF-BH (Supplementary Table 1 ). A strong anomalous peak pinpointed the position of the arsenic atom (corresponding to the phosphorous atom npg a r t i c l e s in TPP) and spatially coincided with R6G ( Fig. 3b) . This finding provided additional unbiased support for the identification of the multidrug-binding site. Overall, there was little structural difference between the apo and drug-bound protein (r.m.s. deviation ~0.5 Å for 446 Cα positions), as supported by the experimental maps calculated for both the apo and R6G-soaked crystal forms ( Supplementary  Fig. 3 ). Because the substrate-binding site is accessible to the periplasm through the solvent-exposed crevice, we suggest that both structures represent an extracellular-facing DinF-BH. Deeply nestled within the transmembrane core domain, the substrate-binding site of DinF-BH contrasts markedly with that of NorM-NG 15 , which is near the membrane-periplasm interface ( Supplementary Fig. 4 ). Within the drug-binding chamber of DinF-BH, amino acid side chains project from TM1, TM2, TM4, TM5, TM6 and TM8 toward R6G (Fig. 3c) . In contrast to NorM-NG, which uses only a few hydrophobic residues in drug binding 15 , copious close-range contacts between DinF-BH and R6G are mediated by hydrophobic amino acids, five of which are aromatic. Specifically, M33 and I44 (in TM1), V56, F60, M63 and M67 (in TM2), F150 and F154 (in TM4), M173 (in TM5) and M286 (in TM8) all make hydrophobic interactions with R6G, whereas Y36, N37 and D40 (in TM1), Y139 (in TM4) and Q206 (in TM6) make either charge-dipole or charge-charge interactions with the bound substrate. Among them, D40 is highly conserved within the DinF subfamily and makes the only ionic contacts with R6G. By contrast, NorM-NG uses four acidic amino acids to bind R6G 15 .
Functional importance of the substrate-binding site
To verify the biological importance of the observed interactions between DinF-BH and R6G, we mutated all the drug-binding amino acids and explored the functional consequences by conducting (b) Fitting of R6G to the electron density map (cyan mesh), which was calculated to 3.7 Å with solvent-flattened MIRAS phases and contoured at 1.5σ. Also shown is the difference anomalous Fourier electron density map (red wire) from the substrate tetraphenylarsonium (TPA), which was calculated to 6.0 Å and contoured at 4σ. Both maps are overlaid onto the final model of R6G (magenta sticks). (c) Close-up of the drug-binding chamber, R6G (magenta). Relevant amino acids are displayed in stick representation, with functionally critical residues labeled in red. npg a r t i c l e s drug-resistance assays (Fig. 4a) . The results revealed that DinF-BH variants M33A, D40A, D40N, D40K, I44A, V56A, M67A, M173A, I200A, Q206A and M286A were all unable to relieve the drug sensitivity of bacteria, probably owing to their impaired transport function, because membranes bearing those mutant proteins showed no response to TPP in the drug/H + antiport assay. By contrast, DinF-BH variants Y36A, N37A, F60A, M63A, Y139A, F150A and F154A retained their ability to confer drug resistance (Fig. 4a) . Altogether, our data ascertained that the internal chamber contains a functionally relevant substrate-binding site, and amino acid side chains at positions M33, D40, I44, V56, M67, M173, Q206 and M286 have pivotal roles in multidrug transport.
Notably, the key electrostatic component of R6G binding is through D40, a residue that appears to have a critical role in selecting for positively charged substrates. Furthermore, D40 is a prime candidate for the cation-binding (protonation) site in DinF-BH. Located within a membrane-embedded chamber that contains numerous hydrophobic amino acids, D40 is effectively shielded from the solvent-exposed crevice by TM7 and TM8 (Supplementary Fig. 4 ). Consistent with this arrangement, the side chain carboxylate of D40 has a calculated pK a of 7.4 (ref. 27 ) and can conceivably undergo cycles of protonation and deprotonation as substrates are shuttled through the transporter in vivo 25, 28 .
By contrast, the membrane-embedded, drug-binding aspartate in NorM-NG (NorM-NG D41 ) is located in a central cavity that is populated with acidic and polar amino acid side chains and is only modestly shielded from the periplasm by extracellular loops 15 ( Supplementary  Fig. 4) . As a consequence, NorM-NG D41 has a calculated pK a of 5.8, which is appreciably lower than that of D40 in DinF-BH. Apparently, the arrangement of TM7 and TM8, as well as the hydrophobicity of the substrate-binding sites in NorM-NG and DinF-BH, perturbs the pK a of side chain carboxylates to different extents, rendering D40 in DinF-BH chemically more suitable than NorM-NG D41 to serve as a protonation site at physiological pH. Because we obtained the DinF-BH crystals at pH 8.5, it follows that our structures portray a deprotonated transporter.
Direct competition between drug and H +
In support of D40's role as a key cation-binding residue, a protonation-mimetic mutation D40N, which presumably 'locks' D40 in its protonated state, abrogated the ability of DinF-BH to confer drug resistance or to catalyze drug/H + exchange (Fig. 4b) . Indeed, the D40N mutation drastically reduced the R6G binding affinity of DinF-BH (Fig. 4c) . Additionally, treatment of DinF-BH with dicyclohexylcarbodiimide, a chemical that reacts with protonated carboxyls in a hydrophobic environment 25 , abolished the binding of R6G to DinF-BH.
Therefore, membrane-embedded acidic amino acid(s) appears to be essential for the transport function of DinF-BH. Most probably, this is because substrate and H + compete for D40 during multidrug extrusion. In accordance with this competition, H + exerts inhibitory effects on R6G binding to DinF-BH, and this inhibition could be abrogated by mutation D40N (Supplementary Fig. 4) . By contrast, R6G binding to NorM-NG was insensitive to the H + concentrations, consistent with NorM-NG being a Na + -coupled rather than an H + -coupled transporter 8 . Furthermore, analysis of the pH-dependent R6G binding to DinF-BH revealed a pK a of ~7.2 for the competing H + , a result probably reflecting the effects of D40 protonation on R6G binding, because H + could no longer interfere with the binding when D40 was replaced by an nonprotonatable residue.
To confirm the direct competition between drug and H + , we studied drug-triggered H + release by using a fluorescent pH indicator 25, 28 . Addition of substrate triggered a stoichiometric (1:1) release of H + from DinF-BH (Fig. 4d) . Because our structure indicated a single drug-binding site in DinF-BH (Fig. 3b) , it follows that each substrate induces the release of a single H + from the transporter. Furthermore, the mutation D40N abolished the ability of DinF-BH to release H + upon drug binding (Fig. 4e) , thus suggesting that substrate triggers H + release by directly binding D40. Taken together, our data are consistent with a direct competition between H + and drug, which is essential for the antiport function of DinF-BH. This ligand-sharing arrangement of cation-and substrate-binding sites is distinct from that of NorM-NG, in which substrate and cation interact with completely different subsets of amino acids 15 . 
npg a r t i c l e s
Modeling the intracellular-facing conformation Although our DinF-BH structures represent an extracellular-facing conformation of the transporter, we reasoned that the conformation of the extracellular halves of TM7 and TM8 reflects that in the intracellular-facing state, as they pack snugly against TM1 and TM2, thereby occluding the interface between the N and C domains from the periplasm (Fig. 2b) . We also anticipated that in the intracellularfacing DinF-BH, TM9-TM12 interact closely with TM7 and TM8, so that the wide crevice in the C domain can be sealed off to occlude the drug-binding site from the periplasm.
We generated an intracellular-facing model of DinF-BH on the basis of these considerations, (Fig. 5a) . Without causing any obvious steric clashes, we rotated the cytoplasmic halves of TM7 and TM8, as well as TM9-TM12, by 20° relative to the rest of the protein. Notably, the rotation of TM9-TM12 collapsed the solvent-exposed crevice within the C domain, whereas the rotation of TM7 and TM8 exposed the drugbinding site toward the cytoplasm (Fig. 5b) . In so doing, the intracellular and extracellular halves of both TM7 and TM8 moved to different extents, rather than tilting as rigid bodies. This motion effectively straightened the kinks in TM7 and TM8, and it may be well accommodated by the proline (P247 and P291) and glycine (G245 and G294) residues as well as the 18-residue intracellular loop between TM6 and TM7.
Functional importance of TM7 and TM8 in DinF-BH
We further predicted that the perturbation of the intracellular transport pathway in DinF-BH would affect the conformational changes and/or substrate binding required for drug translocation, thereby altering the transport function, as often happens in membrane transporters [29] [30] [31] . Henceforth, we individually mutated 11 amino acids along the intracellular transport path in DinF-BH and probed their impact on the transport function by conducting drug-resistance assays (Fig. 5c,d) . We found that mutations of L22, V241, V244, F249 and Q297 all impaired the ability of DinF-BH to confer cellular resistance to drugs. In keeping with these results, those mutations also abolished the drug/H + exchange activity of DinF-BH in everted membrane vesicles.
To delve more deeply into the functional roles of those amino acids, we purified mutant proteins L22A, V241A, V244A, F249A and Q297A, which were expressed to the same level as was the wild-type protein and appeared to be well folded on the basis of gel-filtration chromatography. We then carried out the fluorescence-based H + -release assay and observed that all the mutant proteins released a stoichiometric H + upon TPP binding, as did the wild-type protein (Fig. 4d) . Altogether, our analyses indicated that L22, V241, V244, F249 and Q297 have crucial roles in the transport function, as single alanine substitutions of those amino acids had no deleterious consequence on the expression or solution behavior of DinF-BH. Apparently, druginduced H + -release was not affected by those mutations, thus implying that those amino acid side chains participate in the interconversion between the intracellular-and extracellular conformations rather than directly binding substrates. Notably, V241, V244 and F249 are located in the intracellular half of TM7, whereas Q297 lies in that of TM8. Therefore, our data showed high concordance with the putative structural rearrangement of TM7 and TM8 during the transition from the extracellular-to intracellular-facing state (Fig. 5a,b) . 
Functional importance of TM7 and TM8 in NorM-NG
To make greater inroads in understanding MATE-mediated transport, we used the intracellular-facing model of DinF-BH as a template to map the intracellular transport route in NorM-NG, given their structural similarity (r.m.s. deviation of 2.97 Å for 279 common Cα positions). We generated 12 NorM-NG mutants, each with a mutation targeting a solvent-exposed amino acid along the cytoplasm-facing transport route (Supplementary Fig. 5 ). We then examined the function of those NorM-NG variants by using the drug-resistance assay. Notably, mutations Q34A, I68A, I254A, Y258A, M295A, T305A and R388A abolished the ability of NorM-NG to relieve the sensitivity of bacteria toward drugs (Supplementary Fig. 5 ). Furthermore, those mutations severely impaired the R6G-efflux activity of NorM-NG.
Among them, I254, Y258, M295 and T305 are located within the cytoplasmic portions of TM7 and TM8 in NorM-NG ( Supplementary  Fig. 5 ). These findings thus further substantiated the functional importance of the intracellular halves of TM7 and TM8. Additionally, TM7 and TM8 in NorM-NG had both been implicated in the Na + -induced conformational changes during drug export 15 . Collectively, our data suggested that TM7 and TM8 have important roles in the transport function of NorM-NG and DinF-BH, consistent with a similar intracellular transport pathway among those prokaryotic MATE homologs.
Proposed antiport mechanism
With both the extracellular-and intracellular-facing models in hand, we can now describe the major steps during the transport cycle for DinF-BH (Fig. 6) . In our working hypothesis, H + disrupts drug binding by competing directly for D40 in the extracellular-facing, drug-bound transporter (state I). The resulting extracellular-facing, protonated transporter (state II) then switches to the intracellularfacing and protonated state, and this transition involves a 20° rotation of the cytoplasmic halves of TM7 and TM8 as well as TM9-TM12 relative to the rest of the protein (state III). This rotational movement, probably driven by thermal energy, enables the transporter to capture new substrate from the cytoplasm. Drug binding then triggers deprotonation of the transporter by directly competing for D40 (state IV). The intracellular-facing, drug-bound transporter can then return to the extracellular-facing, drug-bound state to begin another transport cycle (state I).
Our results further suggested a key difference between NorM-NG and DinF-BH in the mode of interaction between the substrate and counter-transported cation. In NorM-NG, cation-and substratebinding sites are spatially well-separated, a result hinting that Na + induces drug extrusion through an indirect competition mechanism, i.e., through protein conformational changes 15 ( Supplementary  Fig. 6 ). By contrast, in DinF-BH, H + is likely to trigger drug release by competing for a substrate-binding amino acid (D40), during which no substantial rearrangement of transmembrane helices would be necessary (Fig. 6) . This mechanistic disparity points to striking functional diversity between NorM and DinF transporters despite their structural similarity, thereby challenging the routinely made assumption that all MATE proteins share a common antiport mechanism 14, 32 .
DISCUSSION

Structural diversity within the DinF branch
After we had determined the structures of DinF-BH, the crystal structures of an H + -coupled, extracellular-facing DinF transporter from Pyrococcus furiosus (pfMATE) were reported at 2.1-Å to 3.0-Å resolutions 32 . In particular, the authors determined the pfMATE structures at both high (7.0-8.0) and low (6.0-6.5) pH, and both resemble that of substrate-free NorM-VC 14 and are largely identical except that TM1 is more bent in the low-pH structure. Moreover, the authors identified the binding site for a norfloxacin analog (Br-NRF) and proposed an antiport mechanism wherein the protonation of D41 (the cation-binding site) in pfMATE triggers the bending of TM1 to extrude drugs.
Both DinF-BH and pfMATE contain a conserved aspartate in TM1 (DinF-BH D40 and pfMATE D41 ), and both share appreciable amino acid sequence similarity (27% identity). By contrast, DinF-BH bears only 11% amino acid sequence identity to NorM-NG. Unlike DinF-BH D40 , however, pfMATE D41 is readily accessible from a solvent-filled cavity that is formed between the pseudosymmetric TM1-TM6 and TM7-TM12 (Supplementary Fig. 7) . Notably, in both the highand low-pH structures, pfMATE D41 has a calculated pK a of <3. 6 (ref. 27) , substantially lower than that of DinF-BH D40 . The structural and chemical differences of this conserved, protonatable amino acid between DinF-BH and pfMATE, if real, would imply a divergent evolution of the two transporters.
Moreover, there are critical differences between the antiport mechanisms proposed for pfMATE and DinF-BH. In pfMATE, the coupling between H + and substrate was suggested to be mediated by the Figure 6 Proposed transport mechanism for DinF-BH. Bundles of transmembrane helices are drawn as rectangles, with TM1-TM6 colored cyan, TM7-TM8 red (extracellular halves) and yellow or gray (intracellular portions) and TM9-TM12 yellow or gray. Drug and proton are drawn as a magenta oval and a green circle, respectively. D40 is colored and labeled in black. During transport, protonation of D40 in extracellular-facing, drug-bound DinF-BH (state I) triggers drug release. The protonated, extracellular-facing DinF-BH (state II) then switches to the protonated, intracellular-facing state (III) by undergoing a rotational movement as described in the text. Drug binding to DinF-BH from the cytoplasm subsequently promotes the deprotonation of D40 and yields the drugbound, intracellular-facing state (IV), which eventually returns to the drug-bound, extracellular-facing state (I). npg a r t i c l e s bending or straightening of TM1 and to be allosteric in nature 32 . In DinF-BH, however, we contend that H + and substrate compete for a shared binding site, i.e., there is direct coupling. We also argue that TM7 and TM8 in DinF-BH shield D40 from the bulk solvent so that its side chain carboxylate can serve as a protonation site in vivo.
Different substrate-binding sites
Besides their cation-binding sites, the substrate-binding sites also differ substantially among DinF-BH, NorM-NG and pfMATE (Supplementary Fig. 7 ). Our studies herein revealed a multidrug-binding chamber in DinF-BH that contains numerous hydrophobic amino acids, including three phenylalanines and two tyrosines. The largely hydrophobic substrate-binding chamber in DinF-BH markedly contrasts with the drug-binding cavity in NorM-NG, which is composed mainly of acidic and polar amino acids 15 . In NorM-NG, most of the close-range interactions between the protein and bound substrate are mediated by charge-charge and charge-dipole interactions, and only one aromatic amino acid makes direct contacts with the bound substrate. In DinF-BH, by contrast, D40 makes the only ionic contacts with the bound substrate. Given the low dielectric constant within the transmembrane domain, the loss of the electrostatic attraction mediated by D40 should considerably weaken substrate binding. Apparently, the hydrophobic drug-binding chamber in DinF-BH provides a suitable chemical environment for D40 to serve a dual function in drug transport: substrate binding and protonation. Despite those differences, the drug-binding sites in NorM-NG and DinF-BH both involve the N and C domains, and both exhibit a surplus of negative charge (Supplementary Fig. 7) , the latter structural feature being consistent with their preferences for transporting cationic substrates.
Notably, the drug-binding site observed in pfMATE is formed exclusively within the N domain 32 , and it is dominated by polar amino acids and exhibits a striking surplus of positive charge ( Supplementary  Fig. 7) . The different locations and surface charges of the substratebinding sites seen among the three MATE transporters were perhaps partly due to the use of chemically distinct substrates in those studies. As such, the current study adds to the burgeoning body of data that point to hitherto-unappreciated mechanistic divergence among MATE transporters, thereby cautioning against treating them as a single class of molecules during the development of pharmaceuticals for overcoming recalcitrant multidrug resistance.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes.
Coordinates and structural factors have been deposited in the Protein Data Bank under accession codes 4LZ6 and 4LZ9. samples (~10 mg/ml) were mixed with an equal volume of a crystallization solution containing 100 mM Tris-HCl, pH 8.5, 100 mM NaCl, 20-30% (vol/vol) PEG400, 0.03% (wt/vol) DDM and 1 mM TCEP. Protein crystals usually appeared within two weeks and continued to grow to full size in a month. For heavy atom derivatization, protein crystals were incubated with 5 mM heavy-metal compounds for 8 h at 22 °C. For substrate soaking experiments, protein crystals were incubated with 0.5 mM R6G or tetraphenylarsonium (TPP analog) for 48 h at 22 °C. The R6G-soaked crystals all had a bright reddish color indicative of the bound substrate.
Structure determination and refinement. More than 3,000 crystals were examined at beamlines 23-ID and 22-ID in Argonne National Laboratory; only a small number (~100) of the crystals were serviceable. X-ray diffraction data were processed with the HKL2000 suite 35 and further analyzed with the CCP4 package 36 unless specified otherwise. All structures were solved with a combination of molecular replacement and MIRAS (multiple isomorphous replacement and anomalous scattering) phasing. Initially, a homology model of DinF-BH based upon the structure of NorM-NG 15 was constructed with the SWISS-MODEL server (http://swissmodel.expasy.org/). The homology model was then placed into the unit cell for the apo crystal form with PHASER 37 . Heavy-metal binding sites were identified by anomalous difference Fourier analysis, and MIRAS phases were subsequently calculated with SHARP 38 for the apo and R6G-bound crystal forms. Table 1 lists the optimal subset of derivative data for MIRAS phasing. The resulting electron density maps were further improved by solvent flattening, histogram matching, cross-crystal averaging and phase extension. Both the protruding electron densities for some aromatic amino acid side chains and heavy metal-binding sites were used as markers to aid protein sequence assignment (Supplementary Table 2 ). Regions of the structures of NorM-NG and NorM-VC were useful as a guide for model building, which was carried out with the program O 39 . Structure refinement (without TLS parameterization) was conducted with REFMAC with experimental phases as restraints 40 . No attempts were made to model tetraphenylarsonium or to examine the amino acid side chain alterations in DinF-BH upon R6G binding, owing to the modest resolutions of the data. All structure figures were prepared with PyMOL (http://www.pymol.org/). pK a and electrostatic potentials were calculated with PROPKA 27 and PyMOL, respectively. Similar results for pK a prediction were obtained with the H++ web server (http://biophysics.cs.vt.edu/).
